Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Status:
Suspended
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given
together with olaparib in treating patients with ovarian cancer that responds at first to
treatment with drugs that contain the metal platinum but then comes back within a certain
period (recurrent platinum-resistant). Abemaciclib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an
enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP
may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP
inhibitors are a type of targeted therapy. Adding abemaciclib to olaparib may work better to
treat recurrent platinum-resistant ovarian cancer.